Shares of Nightstar Therapeutics PLC (NASDAQ:NITE) have received a consensus broker rating score of 1.00 (Strong Buy) from the four brokers that provide coverage for the stock, Zacks Investment Research reports. Four analysts have rated the stock with a strong buy recommendation.

Analysts have set a 1-year consensus target price of $24.75 for the company, according to Zacks. Zacks has also assigned Nightstar Therapeutics an industry rank of 116 out of 265 based on the ratings given to its competitors.

NITE has been the topic of a number of research reports. BMO Capital Markets initiated coverage on shares of Nightstar Therapeutics in a research note on Monday, October 23rd. They issued an “outperform” rating and a $30.00 target price on the stock. Jefferies Group initiated coverage on shares of Nightstar Therapeutics in a research note on Monday, October 23rd. They issued a “buy” rating and a $25.00 target price on the stock. Leerink Swann initiated coverage on shares of Nightstar Therapeutics in a research note on Monday, October 23rd. They issued an “outperform” rating and a $25.00 target price on the stock. Finally, Wedbush initiated coverage on shares of Nightstar Therapeutics in a research note on Monday, October 23rd. They issued an “outperform” rating and a $19.00 target price on the stock.

A number of institutional investors have recently added to or reduced their stakes in NITE. Nationwide Fund Advisors purchased a new stake in Nightstar Therapeutics during the 3rd quarter worth $1,196,000. Ameriprise Financial Inc. purchased a new stake in Nightstar Therapeutics during the 3rd quarter worth $5,761,000. Chartwell Investment Partners LLC purchased a new stake in Nightstar Therapeutics during the 3rd quarter worth $3,995,000. Sphera Funds Management LTD. purchased a new stake in Nightstar Therapeutics during the 3rd quarter worth $1,728,000. Finally, Citadel Advisors LLC purchased a new stake in Nightstar Therapeutics during the 3rd quarter worth $240,000. 27.12% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Nightstar Therapeutics (NASDAQ:NITE) remained flat at $$13.12 during mid-day trading on Tuesday. 39,966 shares of the company’s stock traded hands, compared to its average volume of 28,450. Nightstar Therapeutics has a 1-year low of $11.99 and a 1-year high of $24.93.

ILLEGAL ACTIVITY NOTICE: “Zacks: Nightstar Therapeutics PLC (NITE) Receives Average Rating of “Strong Buy” from Brokerages” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another site, it was illegally stolen and reposted in violation of international copyright and trademark legislation. The original version of this story can be viewed at https://www.thecerbatgem.com/2018/01/02/zacks-nightstar-therapeutics-plc-nite-receives-average-rating-of-strong-buy-from-brokerages.html.

Nightstar Therapeutics Company Profile

Nightstar Therapeutics PLC, formerly Nightstar Therapeutics Limited, is a clinical-stage gene therapy company. The Company is focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. The Company is developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases.

Get a free copy of the Zacks research report on Nightstar Therapeutics (NITE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Nightstar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics and related stocks with our FREE daily email newsletter.